SLNO has been in the news 409% more than usual
Mar 14, 2026, 12:32 PM
16.96%
What does SLNO do
Soleno Therapeutics, a clinical-stage biopharmaceutical company based in Redwood City, California, focuses on developing novel therapeutics for rare diseases, notably DCCR for Prader-Willi syndrome. DCCR, a once-daily oral tablet, recently completed Phase 3 trials and has received Fast-Track and orphan designations in the U.S. and EU.
SLNO has been in the news recently: Levi & Korsinsky and Kahn Swick & Foti have filed class action lawsuits against Soleno Therapeutics, alleging securities fraud and misrepresentations related to clinical trials for DCCR, covering the period from March 26 to November 4, 2025. Hagens Berman is also encouraging affected investors to report their losses following a 26% drop in the company's stock during the same timeframe.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.